{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:46:23Z","timestamp":1790703983519,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite advances, most patients with multiple myeloma (MM) experience relapse and repeat multiple treatment lines, highlighting an unmet need for patients with relapsed or refractory MM (RRMM). Bispecific antibodies are a new option, but their efficacy and safety in Japanese patients are unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was an analysis of Japanese patients receiving elranatamab monotherapy in MagnetisMM-2 (NCT04798586) and MagnetisMM-3 (NCT04649359). Both studies evaluated a priming dose regimen of elranatamab followed by weekly subcutaneous doses, in patients with disease progression while receiving or who were intolerant to \u22653 prior therapies (\u22651 proteasome inhibitor, \u22651 immunomodulatory drug and\u00a0\u22651 anti-CD38 monoclonal antibody). The primary endpoints were dose limiting toxicities (DLTs) in MagnetisMM-2 and confirmed objective response rate (ORR) in MagnetisMM-3. In both, key secondary endpoints included safety, tolerability, duration of response, time to response, progression-free survival and overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In MagnetisMM-2 (N\u00a0=\u00a04) and MagnetisMM-3 (n\u00a0=\u00a012), median ages were 68.5 and 66.5\u00a0years, respectively. No DLTs were observed in MagnetisMM-2. ORRs were 50.0% (95% CI, 6.8\u201393.2) and 58.3% (95% CI, 27.7\u201384.8) in MagnetisMM-2 and MagnetisMM-3, respectively. All patients experienced treatment-emergent adverse events in MagnetisMM-2 (grade 3\/4: 75.0%) and MagnetisMM-3 (grade 3\/4: 100%); cytokine release syndrome occurred in 100% (grade 3\/4: 25.0%) and 58.3% (no grade 3\/4) of patients, respectively. Neither study reported immune effector cell\u2013associated neurotoxicity syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>No new safety signals were observed, and ORRs were similar to that of the overall MagnetisMM-3 trial population, supporting further studies of elranatamab in Japanese patients with RRMM.<\/jats:p>\n                    <jats:p>ClinicalTrials.gov identifier: NCT04798586 (MagnetisMM-2), NCT04649359 (MagnetisMM-3).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyae068","type":"journal-article","created":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T16:40:01Z","timestamp":1715532001000},"page":"991-1000","source":"Crossref","is-referenced-by-count":16,"title":["Elranatamab in Japanese patients with relapsed\/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3"],"prefix":"10.1093","volume":"54","author":[{"given":"Shinsuke","family":"Iida","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences , Kawasumi Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8602, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III , Division of Hematology and Cell Therapy, , Yamagata, Japan"},{"name":"Yamagata University Graduate School of Medicine , Division of Hematology and Cell Therapy, , Yamagata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisayuki","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine , Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Hematology, Japanese Red Cross Medical Center , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kobe City Medical Center General Hospital , Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Handa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Gunma University Graduate School of Medicine , Maebashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology , Department of Internal Medicine, , Yahaba, Japan"},{"name":"School of Medicine, Iwate Medical University , Department of Internal Medicine, , Yahaba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Kamei","sequence":"additional","affiliation":[{"name":"Pfizer R&D Japan GK , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Pfizer R&D Japan GK , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Japanese Red Cross Medical Center , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"key":"2024090511565094500_ref1","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"2024090511565094500_ref2","doi-asserted-by":"crossref","first-page":"e0283931","DOI":"10.1371\/journal.pone.0283931","article-title":"Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database","volume":"18","author":"Handa","year":"2023","journal-title":"PLoS One"},{"key":"2024090511565094500_ref3","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1002\/ijc.33135","article-title":"Changing trend in mortality rate of multiple myeloma after introduction of novel agents: a population-based study","volume":"147","author":"Usui","year":"2020","journal-title":"Int J Cancer"},{"key":"2024090511565094500_ref4","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1038\/bcj.2015.79","article-title":"Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma","volume":"5","author":"Ozaki","year":"2015","journal-title":"Blood Cancer J"},{"key":"2024090511565094500_ref5","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ajh.23731","article-title":"Clinical profiles of multiple myeloma in Asia\u2014an Asian Myeloma Network study","volume":"89","author":"Kim","year":"2014","journal-title":"Am J Hematol"},{"key":"2024090511565094500_ref6","article-title":"Multiple myeloma","author":"National Cancer Center Japan","year":"2022"},{"key":"2024090511565094500_ref7","doi-asserted-by":"crossref","first-page":"e0285947","DOI":"10.1371\/journal.pone.0285947","article-title":"Survival outcomes among patients with multiple myeloma in the era of novel agents: exploratory assessment using an electronic medical record database in Japan","volume":"18","author":"Uno","year":"2023","journal-title":"PLoS One"},{"key":"2024090511565094500_ref8","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"2024090511565094500_ref9","first-page":"164","article-title":"The management of relapsed and refractory multiple myeloma","volume":"37","author":"Gahvari","year":"2023","journal-title":"Oncology (Williston Park)"},{"key":"2024090511565094500_ref10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"2024090511565094500_ref11","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br J Haematol"},{"key":"2024090511565094500_ref12","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"2024090511565094500_ref13","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2024090511565094500_ref14","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1182\/blood-2022-166494","article-title":"Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma","volume":"140","author":"Raje","year":"2022","journal-title":"Blood"},{"key":"2024090511565094500_ref15","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"key":"2024090511565094500_ref16","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"2024090511565094500_ref17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00277-009-0807-6","article-title":"Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide","volume":"89","author":"Koh","year":"2010","journal-title":"Ann Hematol"},{"key":"2024090511565094500_ref18","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s00277-012-1506-2","article-title":"Low incidence of thromboembolism in relapsed\/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan","volume":"91","author":"Wu","year":"2012","journal-title":"Ann Hematol"},{"key":"2024090511565094500_ref19","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1182\/blood-2005-11-4541","article-title":"Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma","volume":"107","author":"Miyakoshi","year":"2006","journal-title":"Blood"},{"key":"2024090511565094500_ref20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/cas.12335","article-title":"Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization","volume":"105","author":"Yoshizawa","year":"2014","journal-title":"Cancer Sci"},{"key":"2024090511565094500_ref21","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s12185-023-03652-5","article-title":"Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11","volume":"118","author":"Iida","year":"2023","journal-title":"Int J Hematol"},{"key":"2024090511565094500_ref22","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s10147-021-02030-7","article-title":"A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and\/or refractory multiple myeloma","volume":"27","author":"Iida","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"2024090511565094500_ref23","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/jjco\/hyac137","article-title":"Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study","volume":"52","author":"Ishida","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"2024090511565094500_ref24","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1111\/cas.15556","article-title":"Ciltacabtagene autoleucel in patients with relapsed\/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort","volume":"113","author":"Ri","year":"2022","journal-title":"Cancer Sci"},{"key":"2024090511565094500_ref25","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s12185-023-03538-6","article-title":"Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma","volume":"117","author":"Minakata","year":"2023","journal-title":"Int J Hematol"},{"key":"2024090511565094500_ref26","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"2024090511565094500_ref27","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024090511565094500_ref28","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"2024090511565094500_ref29","article-title":"NDA\/BLA multi-disciplinary review and evaluation BLA 761345 Elranatamab","author":"U.S. Food and Drug Administration","year":"2022"},{"key":"2024090511565094500_ref30","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1182\/blood-2022-169971","article-title":"Dose optimization to mitigate the risk of CRS with elranatamab in multiple myeloma","volume":"140","author":"Elmeliegy","year":"2022","journal-title":"Blood"},{"key":"2024090511565094500_ref31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"2024090511565094500_ref32","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"2024090511565094500_ref33","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"2024090511565094500_ref34","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/bloodadvances.2021006178","article-title":"Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma","volume":"6","author":"Mohan","year":"2022","journal-title":"Blood Adv"},{"key":"2024090511565094500_ref35","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood Adv"},{"key":"2024090511565094500_ref36","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/bloodadvances.2021004896","article-title":"Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days","volume":"5","author":"Mikkilineni","year":"2021","journal-title":"Blood Adv"},{"key":"2024090511565094500_ref37","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-023-00808-8","article-title":"Infectious complications of bispecific antibody therapy in patients with multiple myeloma","volume":"13","author":"Sim","year":"2023","journal-title":"Blood Cancer J"},{"key":"2024090511565094500_ref38","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"key":"2024090511565094500_ref39","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"key":"2024090511565094500_ref40","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.1200\/JCO.2022.40.16_suppl.8006","article-title":"Initial safety results for MagnetisMM-3: a phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed\/refractory (R\/R) multiple myeloma (MM)","volume":"40","author":"Lesokhin","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/9\/991\/59016388\/hyae068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/9\/991\/59016388\/hyae068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T19:02:11Z","timestamp":1725562931000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/54\/9\/991\/7681799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5,24]]},"published-print":{"date-parts":[[2024,9,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae068","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,5,24]]}}}